Article info

Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland
Free

Authors

  1. Correspondence to Dr Aron Hjalti Bjornsson, Medicine, National University Hospital of Iceland, 101 Reykjavik, Iceland; aronh{at}landspitali.is
View Full Text

Citation

Bjornsson AH, Grondal G, Kristjansson M ICEBIO, et al
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland

Publication history

  • Received November 19, 2020
  • Revised December 27, 2020
  • Accepted December 29, 2020
  • First published January 5, 2021.
Online issue publication 
April 12, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.